BR112022019632A2 - Marcadores peptídicos e parceiros de ligação - Google Patents

Marcadores peptídicos e parceiros de ligação

Info

Publication number
BR112022019632A2
BR112022019632A2 BR112022019632A BR112022019632A BR112022019632A2 BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2 BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2
Authority
BR
Brazil
Prior art keywords
binding partners
peptide
peptide markers
peptide tags
pairs
Prior art date
Application number
BR112022019632A
Other languages
English (en)
Portuguese (pt)
Inventor
Frederik Sander Bertelsen Adam
Elyette Fougeroux Cyrielle
Susan Thrane
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of BR112022019632A2 publication Critical patent/BR112022019632A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BR112022019632A 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação BR112022019632A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
BR112022019632A2 true BR112022019632A2 (pt) 2023-10-03

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019632A BR112022019632A2 (pt) 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação

Country Status (11)

Country Link
US (1) US20230321260A1 (https=)
EP (1) EP4146675A1 (https=)
JP (2) JP7843245B2 (https=)
KR (1) KR20230006473A (https=)
CN (1) CN115698045A (https=)
AU (1) AU2021268757A1 (https=)
BR (1) BR112022019632A2 (https=)
CA (1) CA3177709A1 (https=)
IL (1) IL297111A (https=)
MX (1) MX2022013938A (https=)
WO (1) WO2021224451A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4593874A2 (en) 2022-09-30 2025-08-06 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
PL3215614T3 (pl) * 2014-11-03 2019-12-31 Merck Patent Gmbh Rozpuszczalne białka fuzyjne inteiny i sposoby oczyszczania biocząsteczek
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Also Published As

Publication number Publication date
KR20230006473A (ko) 2023-01-10
CA3177709A1 (en) 2021-11-11
EP4146675A1 (en) 2023-03-15
AU2021268757A1 (en) 2022-12-08
MX2022013938A (es) 2022-11-30
WO2021224451A9 (en) 2022-05-27
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
JP2026048917A (ja) 2026-03-17
US20230321260A1 (en) 2023-10-12
CN115698045A (zh) 2023-02-03
WO2021224451A1 (en) 2021-11-11
IL297111A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112022019632A2 (pt) Marcadores peptídicos e parceiros de ligação
CL2021003373A1 (es) Nuevos inhibidores de egfr
BR112022006977A2 (pt) Aminas bicíclicas como inibidores de cdk2
CO2019009365A2 (es) Anticuerpos anti-lag3
MX2020004145A (es) Variantes de desoxirribonucleasa (dnasa).
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CR20190427A (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap
BR112022005995A2 (pt) Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
MX2020003857A (es) Anticuerpos anti-tau y uso de los mismos.
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
CO2023015915A2 (es) Anticuerpos anti-ccr8
CL2018003655A1 (es) Procedimiento de fabricación de briquetas que contienen un compuesto calcio-magnesiano y un compuesto a base de hierro, y briquetas así obtenidas.
BR112017024676A2 (pt) ?métodos para produzir biohidrocarbonetos e mistura de biohidrocarbonetos?
MX2023008631A (es) Montajes de muelle helicoidal abierto.
BR112018068103A2 (pt) anticorpos gitr, métodos e usos
BR112016028502A2 (pt) elemento de segurança, documento de identificação e método para produzir o elemento de segurança
MX362094B (es) Marcadores de diagnostico para el tratamiento de trastornos proliferativos celulares con inhibidores de telomerasa.
MX379400B (es) Combinaciones novedosas de un antagonista de h3 y un inhibidor de recaptacion de noradrenalina y sus usos terapéuticos.
MX2017012924A (es) Metodos para seleccionar inhibidores selectivos de fosfatasa e inhibidores no selectivos de fosfatasa.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
EP3987514C0 (en) SCENE-BASED AUDIO DATA CORRELATION FOR PSYCHOACOUSTIC AUDIO CODING
CL2024003023A1 (es) Inhibidores lrrk2.
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente